SGLT-2 inhibitors - An assessment of the German oral therapeutic landscape for people with type 2 diabetes

被引：0

作者：

Aberle, Jens ^{[1
]}

Blueher, Matthias ^{[2
]}

Laudes, Matthias ^{[3
]}

Merkel, Martin ^{[4
]}

Sandow, Petra ^{[5
]}

机构：

[1] Univ Klinikum Hamburg Eppendorf, Endokrinol & Diabetol, Univ Adipositaszentrum Hamburg, Hamburg, Germany

[2] Univ Med Leipzig, Helmholtz Inst Metab Adipositas & Gefassforsch HI, Leipzig, Germany

[3] Univ Klinikum Schleswig Holstein, Med Klin 1, Kiel, Germany

[4] Endokrinol Hamburg, Internist Endokrinol Diabetol, Hamburg, Germany

[5] Praxis, Allgemeinmed, Berlin, Germany

来源：

DIABETOLOGIE UND STOFFWECHSEL | 2025年 / 20卷 / 01期

关键词：

SGLT2; type; 2; diabetes; therapy; prevention; comparison; POST-HOC ANALYSES; CARDIOVASCULAR OUTCOMES; KIDNEY-DISEASE; DAPAGLIFLOZIN; MELLITUS; PREVENTION; EFFICACY; PLACEBO; SAFETY;

D O I：

10.1055/a-2549-1472

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

As numerous extensive studies have shown, SGLT2 inhibitors not only have beneficial effects on glucose metabolism, but also have a pronounced protective effect on the heart and kidneys. This class of drugs therefore plays an important role in the primary and secondary prevention of diabetes-associated comorbidities. Based on the evidence for SGLT2 inhibitors, guidelines recommend their early use in people with type 2 diabetes being at high risk of cardiovascular and/or renal events. However, prescription data show that these recommendations are currently not implemented and that significantly more people with type 2 diabetes could benefit from organ-protective therapy. Therefore, the aim of this review is to present the value of SGLT2 inhibitors in comparison to other oral therapeutic approaches for the treatment of type 2 diabetes.

引用

页码：59 / 70

页数：12

共 92 条

[1] Empagliflozin in Heart Failure with a Preserved Ejection Fraction [J].

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Ferreira, Joao P. ;

Bocchi, Edimar ;

Boehm, Michael ;

Brunner-La Rocca, Hans-Peter ;

Choi, Dong-Ju ;

Chopra, Vijay ;

Chuquiure-Valenzuela, Eduardo ;

Giannetti, Nadia ;

Gomez-Mesa, Juan Esteban ;

Janssens, Stefan ;

Januzzi, James L. ;

Gonzalez-Juanatey, Jose R. ;

Merkely, Bela ;

Nicholls, Stephen J. ;

Perrone, Sergio V. ;

Pina, Ileana L. ;

Ponikowski, Piotr ;

Senni, Michele ;

Sim, David ;

Spinar, Jindrich ;

Squire, Iain ;

Taddei, Stefano ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Vinereanu, Dragos ;

Zhang, Jian ;

Carson, Peter ;

Lam, Carolyn Su Ping ;

Marx, Nikolaus ;

Zeller, Cordula ;

Sattar, Naveed ;

Jamal, Waheed ;

Schnaidt, Sven ;

Schnee, Janet M. ;

Brueckmann, Martina ;

Pocock, Stuart J. ;

Zannad, Faiez ;

Packer, Milton .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1451-1461

[2]

[Anonymous], GKV SPITZENVERBAND A

[3] Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study [J].

Aronson, Ronnie ;

Frias, Juan ;

Goldman, Allison ;

Darekar, Amanda ;

Lauring, Brett ;

Terra, Steven G. .

DIABETES OBESITY & METABOLISM, 2018, 20 (06) :1453-1460

[4]

Arzneimittelkommission der deutschen rzteschaft, 2023, Dtsch Arztebl Ausg A, V120, pA685

[5] Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial [J].

Bailey, C. J. ;

Villegas, E. C. Morales ;

Woo, V. ;

Tang, W. ;

Ptaszynska, A. ;

List, J. F. .

DIABETIC MEDICINE, 2015, 32 (04) :531-541

[6] Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial [J].

Bailey, Clifford J. ;

Gross, Jorge L. ;

Hennicken, Delphine ;

Iqbal, Nayyar ;

Mansfield, Traci A. ;

List, James F. .

BMC MEDICINE, 2013, 11

[7] Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications [J].

Bakris, George L. ;

Fonseca, Vivian A. ;

Sharma, Kumar ;

Wright, Ernest M. .

KIDNEY INTERNATIONAL, 2009, 75 (12) :1272-1277

[8] Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report? [J].

Barth, Sebastian Dietmar ;

Kostev, Karel ;

Krensel, Magdalene ;

Mathey, Elke ;

Rathmann, Wolfgang .

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2023, 131 (03) :153-161

[9] Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction Observations From the SAVOR-TIMI 53 Trial [J].

Bergmark, Brian A. ;

Bhatt, Deepak L. ;

McGuire, Darren K. ;

Cahn, Avivit ;

Mosenzon, Ofri ;

Steg, Ph. Gabriel ;

Im, KyungAh ;

Kanevsky, Estella ;

Gurmu, Yared ;

Raz, Itamar ;

Braunwald, Eugene ;

Scirica, Benjamin M. .

CIRCULATION, 2019, 140 (12) :1004-1014

[10] Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease [J].

Bhatt, Deepak L. ;

Szarek, Michael ;

Pitt, Bertram ;

Cannon, Christopher P. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Lewis, Julia B. ;

Riddle, Matthew C. ;

Inzucchi, Silvio E. ;

Kosiborod, Mikhail N. ;

Cherney, David Z. I. ;

Dwyer, Jamie P. ;

Scirica, Benjamin M. ;

Bailey, Clifford J. ;

Diaz, Rafael ;

Ray, Kausik K. ;

Udell, Jacob A. ;

Lopes, Renato D. ;

Lapuerta, Pablo ;

Steg, P. Gabriel .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (02) :129-139

← 1 2 3 4 5 6 7 8 9 10 →